STOCK TITAN

AN2 Therapeutics, Inc. - ANTX STOCK NEWS

Welcome to our dedicated page for AN2 Therapeutics news (Ticker: ANTX), a resource for investors and traders seeking the latest updates and insights on AN2 Therapeutics stock.

AN2 Therapeutics, Inc. (ANTX) is a clinical-stage biopharmaceutical company developing innovative treatments for serious infectious diseases. This news hub provides investors and stakeholders with timely updates on ANTX's progress in addressing conditions like non-tuberculous mycobacterial (NTM) lung disease through its investigational therapies.

Access authoritative information on clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection features official press releases and verified news about ANTX's drug pipeline, research advancements, and corporate announcements.

Key updates include progress on ANTX's lead oral therapeutic candidate, financial reporting disclosures, and collaborations advancing infectious disease treatment. Bookmark this page to stay informed about critical developments in ANTX's mission to transform patient outcomes through targeted biomedical innovation.

Rhea-AI Summary

AN2 Therapeutics, Inc. (ANTX) announced ongoing U.S. enrollment for its pivotal Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease, planning to include Japanese patients. The company has secured a $17.8 million contract from NIAID to develop epetraborole for acute systemic melioidosis. Financially, R&D expenses rose due to trial activities and personnel increases, while G&A costs also increased. As of September 30, 2022, AN2 had $106.4 million in cash, providing a runway through mid-2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.43%
Tags
-
Rhea-AI Summary

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical firm specializing in treatments for severe infectious diseases, announced participation in two investor conferences in November 2022. The Stifel 2022 Healthcare Conference will take place from November 15-17 in New York, where CEO Eric Easom will present on November 16 at 9:10 a.m. ET. Additionally, Easom will join a fireside chat at the 5th Annual Evercore ISI HealthConX Conference on November 30 at 2:15 p.m. ET. Webcasts for both events will be accessible on the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
conferences
-
Rhea-AI Summary

AN2 Therapeutics, Inc. (Nasdaq: ANTX) announced ongoing enrollment in a pivotal Phase 2/3 trial for epetraborole, targeting treatment-refractory Mycobacterium avium complex (MAC) lung disease. The company also presented new findings at the IDWeek 2022 Conference, which took place from October 19-24, 2022. Notable presentations included an oral talk on epetraborole's role as an innovative oral antibiotic and several posters detailing pharmacokinetic studies and dose-response analyses. These efforts emphasize the potential of epetraborole as a critical treatment option for patients with NTM lung disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.38%
Tags
conferences
Rhea-AI Summary

AN2 Therapeutics, Inc. (Nasdaq: ANTX) announced progress in its epetraborole development for treatment-refractory Mycobacterium avium complex (MAC) lung disease. Data from a recent Phase 1 study in Japan supports a 500 mg daily dose. The clinical development strategy prioritizes Japan and the U.S., highlighting their high MAC lung disease prevalence. Additionally, the European Commission granted orphan medicinal product designation for epetraborole in NTM lung disease, providing market exclusivity and support for further development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
none
-
Rhea-AI Summary

AN2 Therapeutics announced a $17.8 million contract from the NIAID to advance epetraborole for treating acute systemic melioidosis, with a base period of $4.3 million. This funding supports preclinical and Phase 1 studies, aiming for a pivotal Phase 2/3 trial. The initiative addresses a significant global health need and potential U.S. biothreat, leveraging existing efforts against Nontuberculous Mycobacterial (NTM) lung disease.

Melioidosis, caused by Burkholderia pseudomallei, poses severe health risks, especially in tropical regions, with a mortality rate of 20-40% even with treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.21%
Tags
none
-
Rhea-AI Summary

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company, announced that Eric Easom, President and CEO, will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The on-demand presentation will be available starting September 12 at 7:00 A.M. E.T. Investors can access the webcast on the AN2 Therapeutics website, with an archived replay available for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.18%
Tags
conferences
Rhea-AI Summary

AN2 Therapeutics (ANTX) reported significant progress in its epetraborole clinical program, initiating a pivotal Phase 2/3 trial for treatment-refractory MAC lung disease in the U.S. and completing a Phase 1 safety study in Japan. The company gained alignment with the PMDA on the use of a microbiological primary endpoint for potential registration in Japan and plans to include Japanese patients in the ongoing trial. Financially, R&D expenses rose to $6.7 million from $3.9 million year-over-year, while G&A expenses increased to $3.6 million from $0.9 million. Cash reserves stood at $115.8 million, sufficient to fund operations through mid-2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
64.66%
Tags
-
Rhea-AI Summary

AN2 Therapeutics (Nasdaq: ANTX) has initiated its pivotal Phase 2/3 clinical trial for epetraborole, a once-daily oral treatment targeting treatment-refractory Mycobacterium avium complex (MAC) lung disease. This trial aims to support regulatory approval using the Limited Population Pathway for Antibacterial and Antifungal drugs (LPAD). Screening of the first patient marks a significant step towards addressing a high unmet medical need. Compelling data from the trial may lead to FDA approval, with topline results expected in mid-2023 and mid-2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
-
Rhea-AI Summary

AN2 Therapeutics (Nasdaq: ANTX) reported strong progress in its clinical and financial activities as of May 10, 2022. The company raised $79.4 million through an upsized IPO, enhancing its balance sheet. AN2 is advancing the epetraborole clinical program, with pivotal Phase 2/3 trial enrollment expected to begin in H1 2022 for MAC lung disease. The FDA has cleared the IND for epetraborole and granted it Fast Track, QIDP, and Orphan Drug designations. Cash reserves stood at $118.4 million, anticipated to sustain operations through mid-2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.81%
Tags
Rhea-AI Summary

AN2 Therapeutics, Inc. (NASDAQ: ANTX) announced the appointment of Maggie FitzPatrick to its Board of Directors. FitzPatrick, a seasoned corporate affairs executive, previously held leadership roles at Johnson & Johnson and Cigna. She is recognized for her expertise in corporate affairs and marketing in healthcare. President and CEO Eric Easom welcomed her, highlighting the expected positive impact on the company's mission to address serious infectious diseases. AN2 is currently developing epetraborole, an oral treatment for NTM lung disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.66%
Tags
management
AN2 Therapeutics, Inc.

Nasdaq:ANTX

ANTX Rankings

ANTX Stock Data

37.92M
23.10M
22.5%
46.31%
0.38%
Biotechnology
Pharmaceutical Preparations
Link
United States
MENLO PARK